Last updated on June 2019

A Multicenter Randomized Double-Blind Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy


Brief description of study

The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2.

The objective of Sub-Study 2 is to evaluate the efficacy and safety of risankizumab compared to placebo in inducing clinical remission in subjects with moderately to severely active UC.

Clinical Study Identifier: NCT03398148

Find a site near you

Start Over

Ucsd /Id# 160452

La Jolla, CA United States
  Connect »

Advanced Research Institute /ID# 161938

New Port Richey, FL United States
  Connect »

Indiana University /ID# 167252

Indianapolis, IN United States
  Connect »

Delricht Research /ID# 206815

New Orleans, LA United States
  Connect »

Gastro One /ID# 160418

Germantown, TN United States
  Connect »

Sagact Pllc /Id# 168776

San Antonio, TX United States
  Connect »

Cemic /Id# 167782

Buenos Aires, Argentina
  Connect »

Sanatorio 9 de Julio S.A. /ID# 167780

San Miguel de Tucuman, Argentina
  Connect »

UZ Brussels /ID# 164176

Jette, Brussels, Belgium
  Connect »

PMI Euromedservice /ID# 204892

Pushkin, Russian Federation
  Connect »

Dr JP Wright /ID# 171138

Cape Town, South Africa
  Connect »

Royal Victoria Infirmary, Newc /ID# 158041

Newcastle Upon Tyne, United Kingdom
  Connect »

City Clinical Hospital #40 /ID# 203370

St. Petersburg, Russian Federation
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.